Hikma Buys Injectables Specialist Custopharm In $400m+ Deal
Deal To Acquire California-Based Firm Will Bolster Hikma’s US Injectables Business
Hikma has agreed to acquire US sterile injectables specialist Custopharm in a deal that includes a $375m upfront purchase price and a further $50m in milestone payments. The transaction is set to bolster Hikma’s near-$1bn injectables business that currently accounts for around two-fifths of turnover.
